Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Debyani Chakravarty


Debyani Chakravarty

Department of Pathology and Laboratory Medicine
Memorial Sloan Kettering Cancer Center
New York, NY

United States of America

Dr. Debyani Chakravarty is a Molecular Geneticist and an Assistant Attending Member of the Molecular Diagnostics Service of the Department of Pathology and Laboratory Medicine at the Memorial Sloan Kettering Cancer Center (MSK). Dr. Chakravarty specializes in clinical cancer genomics and focuses on the accurate clinical interpretation of patient-tumor molecular profiles. Working closely with medical oncologists and molecular pathologists she guides patient-centric care by providing information about the clinical and biological significance of genomic alterations found in cancer.

Dr. Chakravarty is the co-developer and scientific lead of OncoKB, the MSK institutional and FDA-recognized clinical decision support system for tumor molecular profiling. OncoKB provides evidence-based and automated interpretations of the clinical actionability of patient-tumor genetic alterations and annotates ~15,000 molecular pathology sequencing reports at MSK per year.

Dr. Chakravarty is a primary author of the OncoKB index paper and the first author of the American Society of Clinical Oncology (ASCO) provisional clinical opinion on Somatic Genomic Testing in Patients with Metastatic or Advanced Cancer. From 2018 to 2022, she was the Co-Director for the Variant Interpretation for Cancer Consortium (VICC) a driver project for the Global Alliance for Genomics Health (GA4GH). Dr. Chakravarty is also a member of the European Society for Medical Oncology (ESMO) Precision Medicine Working Group. 

Dr. Chakravarty’s current research focuses on characterizing the genomic landscape of pancreatic cancer in patients from diverse and underserved populations as well as identifying methods to increase access to precision oncology treatment strategies for these same patient communities.

Last update: January 2024

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.